Publications

Trends in pharmacological sciences

How important is intestinal cytochrome P450 3A metabolism?

01-05-2009

Drug metabolism and disposition: the biological fate of chemicals

Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.

01-04-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.

01-04-2009

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.

02-03-2009

Drug metabolism and disposition: the biological fate of chemicals

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).

01-02-2009

Advanced drug delivery reviews

Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice.

31-01-2009

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver.

01-01-2009

Drug metabolism and disposition: the biological fate of chemicals

Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.

01-01-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

15-12-2008

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

01-06-2008

Drug metabolism and disposition: the biological fate of chemicals

Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2).

01-04-2008

Molecular pharmacology

Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.

01-03-2008

Antimicrobial agents and chemotherapy

P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.

01-03-2008

Molecular cancer therapeutics

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

01-12-2007

The Journal of clinical investigation

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

01-11-2007

American journal of physiology. Cell physiology

Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.

01-06-2007

Molecular and cellular biology

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

01-02-2007

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

New physiological functions for drug-transporting P-glycoproteins?

10-11-2006

Clinical cancer research : an official journal of the American Association for Cancer Research

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

15-10-2006

The Journal of pharmacology and experimental therapeutics

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

01-07-2006

Carcinogenesis

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

01-01-2006

Trends in pharmacological sciences

The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.

01-01-2006

Cancer chemotherapy and pharmacology

Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).

01-10-2005

International journal of cancer

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

20-09-2005

Stem cells (Dayton, Ohio)

Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice.

01-09-2005

Drug metabolism and disposition: the biological fate of chemicals

Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4.

01-07-2005

Drug metabolism and disposition: the biological fate of chemicals

Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).

01-05-2005

Molecular pharmacology

Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.

01-05-2005

Molecular pharmacology

The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.

01-05-2005

Cancer research

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

01-04-2005

Nature medicine

The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.

01-02-2005

Cancer research

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

15-08-2004

The Journal of pharmacology and experimental therapeutics

Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

01-01-2004

Molecular and cellular biology

Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.

01-11-2003

Cancer research

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

01-10-2003

The Journal of biological chemistry

Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2).

27-06-2003

Cancer research

Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

15-03-2003

The Journal of pharmacology and experimental therapeutics

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

01-02-2003

Advanced drug delivery reviews

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

21-01-2003

Proceedings of the National Academy of Sciences of the United States of America

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

26-11-2002

AIDS (London, England)

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

22-11-2002

Pharmacogenetics

Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1): what are the consequences?

01-11-2002

Cancer research

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

15-04-2002

Key Publication

Molecular cancer therapeutics

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

01-04-2002

Advances in experimental medicine and biology

The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers.

05-01-2002

Genes & development

Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes.

15-09-2001

Cancer research

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

15-04-2001

Molecular pharmacology

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

01-04-2001

Annals of the New York Academy of Sciences

Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.

24-02-2001

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

01-12-2000

How important is intestinal cytochrome P450 3A metabolism?

Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).

Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice.

Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver.

Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2).

Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.

P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

New physiological functions for drug-transporting P-glycoproteins?

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.

Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice.

Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4.

Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).

Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.

The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2).

Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1): what are the consequences?

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers.

Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes.

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

This site uses cookies